Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).
Aguirrebengoa K, Amador C, Amiguet JA, Antela A, Arazo P, Arrizabalaga J, Barros C, Barrufet P, Bassa A, Berenguer J, Castaño M, Clotet B, Coll B, Cordero M, Cuadra F, Cuadrado JM, Cucurull J, Dalmau D, De la Fuente B, Del Pozo MA, Domingo P, Echeverría S, Estrada V, Flores J, Galera CE, Galindo MJ, Gálvez MC, García Henarejos JL, Gaspar G, Gatell JM, Gómez Sirvent JL, Guerrero F, Gutierrez F, Hernández J, Knobel H, López Cortés L, Lozano F, Márquez M, Martín T, Martinez E, Martinénez E, Morano L, Muñoz A, Muñoz J, Ocampo A, Ojea R, Ortega E, Oteo JA, Pascua FJ, Pasquau F, Pasquau J, Pedreira JD, Pedrol E, Peña JM, Pérez-Elías MJ, Podzamczer D, Portilla J, Puig T, Pulido F, Ribera E, Riera M, Rivero A, Rodríguez R, Rubio R, Sanz J, Sanz-Moreno J, Segura F, Sola J, Soriano V, Tarabini P, Telenti M, Terrón JA, Torres-Tortosa M, Veloso S.
Source
Infectious Diseases Unit, H Donostia, San Sebastian, Spain.
Abstract
BACKGROUND:
A hypersensitivity reaction (HSR) is associated with abacavir (ABC), a nucleoside reverse transcriptase inhibitor. Genetic association of ABC HSR with the presence of HLA-B*5701 has been demonstrated in PREDICT-1 study, showing a prevalence of 5.6% in HIV-infected population. However the prevalence of this allele in HIV-infected patients in Spain has not been established yet.
METHOD:
This is a cross-sectional epidemiological study that included 1,198 patients in 74 centers that serve the HIV-infected population of Spain. HLA-B*5701 was checked both in the hospital lab and one central lab, showing an overall prevalence of this allele of 6%.
RESULTS:
HLA-B*5701 was most prevalent in Caucasian population (6.5%). Concordance between the local and central lab was very high for positive and negative results (95.7% and 99.3%, respectively).
CONCLUSION:
These aspects define this test as a useful tool for the management of HIV-infected patients.
- PMID:
- 19362996
- [PubMed - indexed for MEDLINE]
-
Free full text